Literature DB >> 23863863

Nuclear factor-κB pathway-activating gene aberrancies in primary cutaneous large B-cell lymphoma, leg type.

Lianne Koens1, Willem H Zoutman2, Passorn Ngarmlertsirichai3, Grzegorz K Przybylski4, Piotr Grabarczyk3, Maarten H Vermeer2, Rein Willemze2, Patty M Jansen5, Christian A Schmidt3, Cornelis P Tensen2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23863863     DOI： 10.1038/jid.2013.265

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN： 0022-202X            Impact factor:   8.551


× No keyword cloud information.
  14 in total

Review 1.  B cell antigen receptor signaling 101.

Authors:  Joseph M Dal Porto; Stephen B Gauld; Kevin T Merrell; David Mills; Aimee E Pugh-Bernard; John Cambier
Journal:  Mol Immunol       Date:  2004-07       Impact factor: 4.407

2.  Distinct types of primary cutaneous large B-cell lymphoma identified by gene expression profiling.

Authors:  Juliette J Hoefnagel; Remco Dijkman; Katia Basso; Patty M Jansen; Christian Hallermann; Rein Willemze; Cornelis P Tensen; Maarten H Vermeer
Journal:  Blood       Date:  2004-08-12       Impact factor: 22.113

3.  Oncogenically active MYD88 mutations in human lymphoma.

Authors:  Vu N Ngo; Ryan M Young; Roland Schmitz; Sameer Jhavar; Wenming Xiao; Kian-Huat Lim; Holger Kohlhammer; Weihong Xu; Yandan Yang; Hong Zhao; Arthur L Shaffer; Paul Romesser; George Wright; John Powell; Andreas Rosenwald; Hans Konrad Muller-Hermelink; German Ott; Randy D Gascoyne; Joseph M Connors; Lisa M Rimsza; Elias Campo; Elaine S Jaffe; Jan Delabie; Erlend B Smeland; Richard I Fisher; Rita M Braziel; Raymond R Tubbs; J R Cook; Denny D Weisenburger; Wing C Chan; Louis M Staudt
Journal:  Nature       Date:  2010-12-22       Impact factor: 49.962

4.  B cells lacking the tumor suppressor TNFAIP3/A20 display impaired differentiation and hyperactivation and cause inflammation and autoimmunity in aged mice.

Authors:  Yuanyuan Chu; J Christoph Vahl; Dilip Kumar; Klaus Heger; Arianna Bertossi; Edyta Wójtowicz; Valeria Soberon; Dominik Schenten; Brigitte Mack; Miriam Reutelshöfer; Rudi Beyaert; Kerstin Amann; Geert van Loo; Marc Schmidt-Supprian
Journal:  Blood       Date:  2010-11-18       Impact factor: 22.113

5.  Phosphorylation of the CARMA1 linker controls NF-kappaB activation.

Authors:  Karen Sommer; Beichu Guo; Joel L Pomerantz; Ashok D Bandaranayake; Miguel E Moreno-García; Yulia L Ovechkina; David J Rawlings
Journal:  Immunity       Date:  2005-12       Impact factor: 31.745

6.  Protein kinase C inhibitor sotrastaurin selectively inhibits the growth of CD79 mutant diffuse large B-cell lymphomas.

Authors:  Tara L Naylor; Huaping Tang; Boris A Ratsch; Andreas Enns; Alice Loo; Liqing Chen; Peter Lenz; Nigel J Waters; Walter Schuler; Bernd Dörken; Yung-Mae Yao; Markus Warmuth; Georg Lenz; Frank Stegmeier
Journal:  Cancer Res       Date:  2011-02-15       Impact factor: 12.701

7.  Oncogenic CARD11 mutations induce hyperactive signaling by disrupting autoinhibition by the PKC-responsive inhibitory domain.

Authors:  Rebecca L Lamason; Ryan R McCully; Stefanie M Lew; Joel L Pomerantz
Journal:  Biochemistry       Date:  2010-09-28       Impact factor: 3.162

8.  TNFAIP3/A20 functions as a novel tumor suppressor gene in several subtypes of non-Hodgkin lymphomas.

Authors:  Keiichiro Honma; Shinobu Tsuzuki; Masao Nakagawa; Hiroyuki Tagawa; Shigeo Nakamura; Yasuo Morishima; Masao Seto
Journal:  Blood       Date:  2009-07-16       Impact factor: 22.113

9.  Mutations of multiple genes cause deregulation of NF-kappaB in diffuse large B-cell lymphoma.

Authors:  Mara Compagno; Wei Keat Lim; Adina Grunn; Subhadra V Nandula; Manisha Brahmachary; Qiong Shen; Francesco Bertoni; Maurilio Ponzoni; Marta Scandurra; Andrea Califano; Govind Bhagat; Amy Chadburn; Riccardo Dalla-Favera; Laura Pasqualucci
Journal:  Nature       Date:  2009-05-03       Impact factor: 49.962

10.  Constitutive nuclear factor kappaB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells.

Authors:  R E Davis; K D Brown; U Siebenlist; L M Staudt
Journal:  J Exp Med       Date:  2001-12-17       Impact factor: 14.307
View more
  8 in total

1.  Combination of ibrutinib and chemotherapy produced a durable remission in multiply relapsed diffuse large B-cell lymphoma leg type with mutant MYD88 and wildtype CD79.

Authors:  Andrew L Deng; Yu Ri Kim; Emily A Lichtenstein; Owen A O'Connor; Changchun Deng
Journal:  Haematologica       Date:  2017-03-24       Impact factor: 9.941

Review 2.  [Aggressive primary cutaneous B-cell lymphomas and novel EBV+ entities].

Authors:  C Lamos; E Dippel
Journal:  Hautarzt       Date:  2017-09       Impact factor: 0.751

Review 3.  The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas.

Authors:  Rein Willemze; Lorenzo Cerroni; Werner Kempf; Emilio Berti; Fabio Facchetti; Steven H Swerdlow; Elaine S Jaffe
Journal:  Blood       Date:  2019-01-11       Impact factor: 22.113

4.  Excellent Outcome of Immunomodulation or Bruton's Tyrosine Kinase Inhibition in Highly Refractory Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type.

Authors:  Eva Gupta; Joseph Accurso; Jason Sluzevich; David M Menke; Han W Tun
Journal:  Rare Tumors       Date:  2015-12-29

5.  Clinicopathologic significance of MYD88 L265P mutation in diffuse large B-cell lymphoma: a meta-analysis.

Authors:  Ju-Han Lee; Hoiseon Jeong; Jung-Woo Choi; HwaEun Oh; Young-Sik Kim
Journal:  Sci Rep       Date:  2017-05-11       Impact factor: 4.379

6.  Limitations of Monitoring Disease Progression Using Circulating Tumor DNA in Lymphoma: An Example From Primary Cutaneous DLBCL Leg-type.

Authors:  Christopher S Trethewey; Harriet S Walter; Abdullah N M Alqahtani; Ralf Schmid; David S Guttery; Yvette Griffin; Matthew J Ahearne; Gerald S Saldanha; Sandrine P N Jayne; Martin J S Dyer
Journal:  Hemasphere       Date:  2022-03-01

7.  Cell-of-origin classification using the Hans and Lymph2Cx algorithms in primary cutaneous large B-cell lymphomas.

Authors:  Anne M R Schrader; Ruben A L de Groen; Rein Willemze; Patty M Jansen; Koen D Quint; Tom van Wezel; Ronald van Eijk; Dina Ruano; Cornelis P Tensen; Esther Hauben; F J S H Woei-A-Jin; Anne M Busschots; Anke van den Berg; Arjan Diepstra; Maarten H Vermeer; Joost S P Vermaat
Journal:  Virchows Arch       Date:  2022-01-14       Impact factor: 4.535

8.  Novel bioinformatic classification system for genetic signatures identification in diffuse large B-cell lymphoma.

Authors:  Wei Zhang; Li Yang; Yu' Qi Guan; Ke' Feng Shen; Mei' Lan Zhang; Hao' Dong Cai; Jia' Chen Wang; Ying Wang; Liang Huang; Yang Cao; Na Wang; Xiao' Hong Tan; Ken He Young; Min Xiao; Jian' Feng Zhou
Journal:  BMC Cancer       Date:  2020-07-31       Impact factor: 4.430
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.